Project

⦁ Anti-obesity medications which are currently available in the market show limited efficacy and many side effects including gastrointestinal and various neurological symptoms depending on its mode of action. On the other hand, the new drug being developed by JD Bioscience efficiently inhibits lipogenesis in peripheral white adipose tissues with a novel mechanism. In addition, the new drug compound was designed to affect only peripheral tissues excluding central nervous system expecting to show less CNS-related side effects caused by existing appetite suppressants.
⦁ If successful, this compound can be developed as a first-in class new drug to lead the market.

Project Summary

We are developing a new drug for the treatment of obesity and fatty liver disease with a novel mode of action.

Business Model

Development of therapeutics for obesity and the metabolic syndrome targeting peripheral adipose tissues

Main Achievements

Aiming to derive candidate drug for preclinical studies by the end of this year.
We are before filing any patent yet. It will be posted on-line when IP-related issues are cleared.